---
title: 'Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment
  in children with tuberous sclerosis complex (TSC) under 4Â months of age (PROTECT),
  a two-arm, randomized, observer-blind, controlled phase IIb national multicentre
  clinical trial: study protocol'
date: '2025-01-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39762914/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250107170841&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: This study addresses a critical gap in understanding the
  impact of pre-emptive mTOR inhibitor therapy on neuropsychologic outcomes in young
  TSC patients, aiming to improve overall patient outcomes and quality of life. EUCT
  number: 2022-502332-39-00, Registered 22/06/2023, https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2022-502332-39-00.
  ...'
disable_comments: true
---
CONCLUSION: This study addresses a critical gap in understanding the impact of pre-emptive mTOR inhibitor therapy on neuropsychologic outcomes in young TSC patients, aiming to improve overall patient outcomes and quality of life. EUCT number: 2022-502332-39-00, Registered 22/06/2023, https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2022-502332-39-00. ...